At the 2026 American Thoracic Society conference held earlier this year, Insmed showcased encouraging post‑hoc Phase III data for Brinsupri, its first‑to‑market DPP‑1 inhibitor for non‑cystic fibrosis...
Source LinkAt the 2026 American Thoracic Society conference held earlier this year, Insmed showcased encouraging post‑hoc Phase III data for Brinsupri, its first‑to‑market DPP‑1 inhibitor for non‑cystic fibrosis...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.